GlassScriptPhysician profile
Abraham Titus
NPI 1417574880
$4,916.19
in general payments reported to CMS, 2019-2025
43 companies · $2,836 in 2025
The $2,836 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,080 · 2025: $2,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,653 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,653.19 |
| Education | $263.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $596.05 | 2024-2025 | Imfinzi, Calquence, Lynparza |
| Novartis Pharmaceuticals Corporation | $454.06 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $357.96 | 2024-2025 | Opdivo, Reblozyl |
| Incyte Corporation | $348.75 | 2024-2025 | Monjuvi, Jakafi, Monjuvi |
| Celgene Corporation | $318.69 | 2024-2025 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $259.99 | 2024-2025 | Libtayo |
| Pfizer INC. | $235.61 | 2024-2025 | |
| Caris Mpi, INC. | $233.34 | 2025 | Mi Cancer Seek |
| Takeda Pharmaceuticals U.S.A., INC. | $215.30 | 2024-2025 | Iclusig |
| Seagen INC. | $198.00 | 2024-2025 | |
| Abbvie INC. | $140.90 | 2024-2025 | |
| Lilly USA, LLC | $139.59 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $124.46 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $117.73 | 2024-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $115.47 | 2025 | Rybrevant, Carvykti, Erleada |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Titus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.